Professor of Law and Medicine at University of Zurich and ETH Zurich Academic Chair for Regulation in Law, Medicine, and Technology
Joined April 2019
- Tweets123
- Following79
- Followers445
- Likes609
Kerstin Noëlle Vokinger retweeted
In a new Perspective, Kerstin N. Vokinger, MD, JD, PhD, Guanqiao Li, MD, and Olivier J. Wouters, PhD (@ojwouters), write that China has recently emerged as an important player in new drug development — a field traditionally dominated by the United States and Europe. This shift has implications for global access to new medicines. Learn more: nej.md/45SQ0Q7
ALT Perspective "U.S. regulators have had a mixed response to Chinese-made products, including rejecting some drugs tested exclusively in China." "The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally" by Kerstin N. Vokinger, M.D., J.D., Ph.D., Guanqiao Li, M.D., and Olivier J. Wouters, Ph.D.
Kerstin Noëlle Vokinger retweeted
Viewpoint from @james_hillis, Edward Scheffer Cliff, and @KNVokinger: The FDA's recent authorization of an AI-powered medical device for dementia prognosis marks a step in the regulation and clinical implementation of #AI in healthcare. ja.ma/4fwUX4N
New study @TheLancet
WHO shapes priorities for the world’s most influential medicines list?
We analyzed applicants for WHO essential medicines list and discuss solutions to improve access to essential medicines
thelancet.com/journals/lance…
w/ @kjmeetswrld @CamilleGla52655
Kerstin Noëlle Vokinger retweeted
Was sie mit den steigenden Krankenkassenprämien zu tun hat: Die Angstgegnerin – eine Professorin legt sich mit der Pharmabranche an nzz.ch/schweiz/der-pharmasch…
Kerstin Noëlle Vokinger retweeted
🗞️Kerstin Noëlle Vokinger: ‘New cancer therapies are being approved for patient groups not included in clinical trials’
Read more 👇 english.elpais.com/health/20…
Kerstin Noëlle Vokinger retweeted
Kerstin Noëlle Vokinger: “Las nuevas terapias contra el cáncer son aprobadas para perfiles de pacientes no incluidos en los ensayos”
Investigadores de Zurich, Yale y Harvard revelan diferencias que pueden reducir la seguridad y eficacia
elpais.com/sociedad/2024-09-… vía @el_pais
New study @AnnalsofIM
We assessed time from approval until reimbursement of new drugs in US, Germany, England, France, and Switzerland (2011-2022)
@CamilleGla52655, @miquelsb2, @DusetzinaS
With coverage @NZZ
tinyurl.com/26jgq23c
A new report finds that the U.S. lags behind European countries in time from drug approval to reimbursement. This is important because while approval enables market entry of new drugs, insurance reimbursement is what determines patient access: ecs.page.link/kEfsQ
Kerstin Noëlle Vokinger retweeted
Drug prices declined substantially after patent expiration across 8 high-income countries, from 30% to 80% during the 8 years after patent expiration. ja.ma/3yDG4NV @KNVokinger
Kerstin Noëlle Vokinger retweeted
Viewpoint compares use and costs of GLP-1 receptor agonists for weight loss between the US and 3 other peer countries. ja.ma/3LnIfI2
Kerstin Noëlle Vokinger retweeted
Happy to share our new perspective article in @TheLancetOncol highlighting shortages of #essential (and #curative) #cancer medicines
thelancet.com/journals/lanon…
Kudos to amazing co-authors @kjmeetswrld @KNVokinger
@ImperialSandC @UZH_en @LSEHealthPolicy @imperialcollege
Kerstin Noëlle Vokinger retweeted
Neujahr ist die Zeit für neue Regeln – jedes Jahr treten Hunderte davon in Kraft. Doch wer ist dafür verantwortlich, und wo wird am meisten vorgeschrieben? Ein Zürcher Forschungsteam hat dies untersucht.
Von @DanielGerny
nzz.ch/schweiz/es-gibt-immer…
Kerstin Noëlle Vokinger retweeted
Global competition between countries on the successful development of AI technologies has emerged over the past decade, with medicine at the forefront of interest. This study finds that China dominated in terms of absolute number of trials. Read more: nejm.ai/40AE2re
ALT Figure 4. Geographic Distribution of Clinical Trials for AI/ML-Enabled Medica lDevices.
ALT Figure 5. Temporal Trends for Clinical Trials for AI/ML-Enabled Medical Devices by Continent.
New study geographic representation of trials for AI med devices @NEJM_AI: 97% national. Approx half in China, followed by US & Japan nejm.ai/40AE2re.
Funded by @snsf_ch
Covered by Swiss National News @srfnews @georg_halter w/ @FrauenfelderTh
srf.ch/news/schweiz/neue-stu…
Kerstin Noëlle Vokinger retweeted
Thinking the future of essential medicines @WHO. Great thoughts with incredible talents and scientific superstars
New study @AnnalsofIM: Review duration of drugs longer&applications later submitted in Europe vs US-patients benefit if time difference in submission is further minimized
@miquelsb2, @CamilleGla52655, @thomasmd, @akesselheim,@PORTAL_Research,@BWHUrology
acpjournals.org/doi/10.7326/…
Covered in @tagesanzeiger tagesanzeiger.ch/studie-zu-m…
1
271
New study @LancetDigitalH: Analysis of 510(k) predicate network of AI medical devices.
Tasks of AI medical devices change over time and may raise safety issues.
thelancet.com/journals/landi…
@Captcoma, @cxbln, @Unispital_USZ
funded by @snsf_ch
covered by @NZZ
Auch in Spitälern hält KI Einzug. Eine Medizinerin macht auf Risiken aufmerksam und kritisiert den Plan, amerikanische Medizinprodukte automatisch auch in der Schweiz zuzulassen.
nzz.ch/wissenschaft/ki-in-de…
New piece: Drugs increasingly approved for many indications. Findings indicate substantially lower R&D costs for supplemental indications compared to first indications. More public data necessary to validate findings.
with @ojwouters @LSEHealthPolicy
jamanetwork.com/journals/jam…
Cancer premium: Cancer drugs 3x more expensive than non-cancer drugs after adjusting for efficacy, prevalence, incidence & mortality.
thelancet.com/journals/eclin…
with @miquelsb2, @TheWonkologist
Funding: @snsf_ch
Covered by El Pais shorturl.at/cpLT0 & Swiss national news:
#Krebsmedikamente sind dreimal teurer als andere Medikamente: Das zeigt eine neue Studie. Eine medizinische Erklärung für den Preisunterschied konnten die Forscherinnen und Forscher nicht finden. srf.ch/news/schweiz/brisante…
